Oncocyte (NASDAQ:IMDX – Get Free Report) and WAVE Life Sciences (NASDAQ:WVE – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.
Profitability
This table compares Oncocyte and WAVE Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncocyte | -2,955.63% | N/A | -107.52% |
| WAVE Life Sciences | -309.73% | -50.36% | -40.06% |
Earnings & Valuation
This table compares Oncocyte and WAVE Life Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncocyte | $4.05 million | 33.37 | -$50.22 million | ($1.49) | -2.77 |
| WAVE Life Sciences | $42.73 million | 22.41 | -$204.38 million | ($1.09) | -4.46 |
Oncocyte has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Oncocyte has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -1.3, indicating that its stock price is 230% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Oncocyte and WAVE Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncocyte | 1 | 0 | 2 | 0 | 2.33 |
| WAVE Life Sciences | 1 | 1 | 14 | 0 | 2.81 |
Oncocyte presently has a consensus price target of $10.50, indicating a potential upside of 154.24%. WAVE Life Sciences has a consensus price target of $22.31, indicating a potential upside of 359.10%. Given WAVE Life Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Oncocyte.
Insider & Institutional Ownership
55.3% of Oncocyte shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
WAVE Life Sciences beats Oncocyte on 9 of the 14 factors compared between the two stocks.
About Oncocyte
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
About WAVE Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.
